Flow Forward Medical Inc. is developing the Arteriovenous Fistula Eligibility (AFE) Systemâ¢, an small, temporary, external blood pump that is designed to stimulate flow-mediated dilation in order to make more patients eligible for an arteriovenous fistula (AVF) an dincrease success rates of hemodialysis. In 2017 the firm reported completing a preclinical study and a computational fluid dynamics study of the Arteriovenous Fistula Eligibility system. The device is a small, minimally invasive blood pump system designed for temporary use to rapidly dilate peripheral veins through flow-mediated vascular dilation prior to arteriovenous fistula surgery. Flow Forward was initially founded in 2011 as a subsidiary of Novita Therapeutics, LLC, a privately held life sciences incubator, but subsequently - in 2014 -spun out as an independent entity
